Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this drugmaker have returned -4.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be headed in ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers are better ...

合作内容 - Vertex Pharmaceuticals Incorporated和TreeFrog Therapeutics合作开发针对1型糖尿病的细胞治疗技术[1] - Vertex获得了TreeFrog的C-Stem™技术的独家许可，以优化其针对1型糖尿病的细胞治疗生产[1] - Vertex将与TreeFrog合作，以扩大TreeFrog的细胞生产和繁殖技术，为1型糖尿病治疗提供支持[1] 技术优势 - TreeFrog的C-Stem™技术模拟自然微环境，使细胞在3D中呈指数增长，有助于Vertex生产大量完全分化的细胞[2] 目标与意义 - Vertex和TreeFrog的合作旨在改变1型糖尿病的治疗方式，为患者提供先进的细胞治疗方案[3]

合作协议 - Vertex Pharmaceuticals与TreeFrog Therapeutics签署了一项许可和合作协议，以优化VRTX的1型糖尿病（T1D）细胞疗法的生产[1] - Vertex将利用TreeFrog的专有细胞制造技术C-Stem，增强其生成大量完全分化的胰岛素产生细胞的能力[2] - Vertex将向TreeFrog支付2500万美元的前期费用，同时对合作伙伴公司进行股权投资[4]

Vertex obtains an exclusive license to TreeFrog's C-StemTM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vert ...

Could Vertex's growth story continue? Vertex Pharmaceuticals (VRTX 0.20%) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of cystic fibrosis (CF) failed along the development path. But the company continued to impress with its CF products and their revenue growth as well as its advancement of other non-CF candidates in the pipeline. If you'd invested $10,000 in Vertex five years ago, you would have ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has granted a rolling new drug application (NDA) submission for suzetrigine (formerly known as VX-548) in moderate-to-severe acute pain. The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024. Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $394.17, reflecting a -0.8% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq added 0.12%. The drugmaker's stock has dropped by 3.41% in the past month, exceeding the Medical sector's loss of 5.81% and lagging the S&P 500's loss of 0.9%. Investors will be eagerly watching for the perf ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average brokerage recommendation (ABR) ...

Vertex just laid claim to an asset that might be very valuable. Biotech acquisitions continue to abound this year. On April 10, Vertex Pharmaceuticals (VRTX -0.92%) announced it would purchase Alpine Immune Sciences (ALPN -0.05%) for $4.9 billion in cash in a deal that's set to close before the end of this quarter. The prized asset that Vertex will gain as part of this purchase is ALPN-303, a potential autoimmune treatment that's in phase 2 clinical trials. But there's a lot more to the deal's potential val ...